Patrick Neven

University Hospitals Leuven
Country flagBelgium

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (23)

Background: Breast cancer is one of the most common cancers worldwide, with both the disease and the treatments affecting patients’ quality of life and overall survival. Patient preference studies can help to identify what matters most to patients. This study aims to provide an overview of published patient preference studies in breast cancer, focusing on (i) the design of the study, (ii) preference outcomes including preference heterogeneity, (iii) recruitment strategies, and (iv) patient involvement. Methods: For this scoping review, a search strategy was created for five databases (PubMed, Embase, Scopus, Web of Science Core Collection, and CINAHL), based on the concepts ‘breast cancer’ and ‘patient preference’. The articles were screened double-blind in two phases, after which, the relevant data was extracted and analyzed. Results: A total of 31 articles were selected based on the eligibility criteria. The studies were published over a wide time range (1995–2024), and across different countries. Different methodologies were used, and different attributes were included, mainly related to adverse events of treatments and survival elements. Survival elements were almost always considered important when included. Preference heterogeneity was assessed in 24 of the included studies. The involvement of patients in these studies varied; in two studies, patients were involved in an advisory board; in five studies, patients provided feedback on the preference study conduct via interviews or focus group discussions; and in twelve studies, pilot tests were mentioned. Conclusions: The studies show diverse methods, outcomes, and patient involvement strategies. This may complicate the implementation of preferences in decision-making, suggesting preference studies with clear objectives and implementation strategies to create impact for and with patients.

Year:

2025

Purpose: Patients with postpartum breast cancer diagnosed after cessation of breastfeeding (postweaning, PP-BC PW ) have a particularly poor prognosis compared with patients diagnosed during lactation (PP-BC DL ), or to pregnant (Pr-BC) and nulliparous (NP-BC) patients, regardless of standard prognostic characteristics. Animal studies point to a role of the involution process in stimulation of tumor growth in the mammary gland. However, in women, the molecular mechanisms that underlie this poor prognosis of patients with PP-BC PW remain vastly underexplored, due to of lack of adequate patient numbers and outcome data. Experimental Design: We explored whether distinct prognostic features, common to all breast cancer molecular subtypes, exist in postpartum tumor tissue. Using detailed breastfeeding data, we delineated the postweaning period in PP-BC as a surrogate for mammary gland involution and performed whole transcriptome sequencing, immunohistochemical, and (multiplex) immunofluorescent analyses on tumor tissue of patients with PP-BC PW , PP-BC DL , Pr-BC, and NP-BC. Results: We found that patients with PP-BC PW having a low expression level of an immunoglobulin gene signature, but high infiltration of plasma B cells, have an increased risk for metastasis and death. Although PP-BC PW tumor tissue was also characterized by an increase in CD8 + cytotoxic T cells and reduced distance among these cell types, these parameters were not associated with differential clinical outcomes among groups. Conclusions: These data point to the importance of plasma B cells in the postweaning mammary tumor microenvironment regarding the poor prognosis of PP-BC PW patients. Future prospective and in-depth research needs to further explore the role of B-cell immunobiology in this specific group of young patients with breast cancer.

Year:

2025

Purpose: Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in this study, we present PD data from the EMBER-2 study. Patients and Methods: Postmenopausal women with untreated, operable estrogen receptor (ER)–positive, HER2-negative early breast cancer were randomized to 400 versus 800 mg of imlunestrant daily for ∼2 weeks before surgery. A single arm study tested a daily dose of 200 mg. PD biomarker changes (ER, progesterone receptor, Ki-67 by IHC, and mRNA expression of ER-related genes) were evaluated in paired tumor samples (pre-/posttreatment). Safety and pharmacokinetics were also assessed. Results: Among evaluable paired samples ( n = 75), PD profiles demonstrated consistent ER targeting between 400- and 800-mg doses, with less toxicity at the 400-mg dose. Although inducing the lowest rate of complete cell-cycle arrest, PD and pharmacokinetic results were similar for the 200-mg dose. Conclusions: EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.

Year:

2024

Purpose: Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER + ), HER2 − metastatic breast cancer and tumors harboring estrogen receptor 1 ( ESR1 ) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i). In patients with ESR1 -mutated tumors, we evaluated the efficacy and safety of elacestrant versus SOC based on prior ET+CDK4/6i duration and in clinical subgroups with prior ET+CDK4/6i ≥12 months. Patients and Methods: EMERALD, an open-label phase III trial, randomly assigned patients with ER + , HER2 − metastatic breast cancer who had received 1–2 prior lines of ET, mandatory CDK4/6i, and ≤1 chemotherapy to elacestrant (345 mg daily) or SOC (aromatase inhibitor or fulvestrant). PFS was assessed across subgroups in post hoc exploratory analyses without adjustment for multiple testing. Results: In patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months, the median PFS for elacestrant versus SOC was 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26–0.63). In this population, the median PFS (in months) for elacestrant versus SOC was 9.1 versus 1.9 (bone metastases), 7.3 versus 1.9 (liver and/or lung metastases), 9.0 versus 1.9 ( PIK3 catalytic subunit α mutation), 8.6 versus 1.9 (tumor protein p53 gene mutation), 9.0 versus 1.9 (HER2-low), 9.0 versus 1.9 ( ESR1 D538G -mutated tumors), and 9.0 versus 1.9 ( ESR1 Y537S/N -mutated tumors). Subgroup safety was consistent with the overall population. Conclusions: The duration of prior ET+CDK4/6i ≥12 months in metastatic breast cancer was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC and was consistent across all subgroups evaluated in patients with ER + , HER2 − , ESR1 -mutated tumors.

Year:

2024

PFS according to mutation and molecular expression subgroups. Kaplan–Meier estimates of PFS in patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months who, at screening, had the presence of ( A ) PIK3CA -mut ( n = 62; 39%); ( B ) PIK3CA wild-type ( n = 97; 61%); ( C ) TP53 -mut ( n = 61; 38%); ( D ) TP53 wild-type ( n = 97; 61%); ( E ) HER2-low expression ( n = 77; 48%); ( F ) HER2-zero expression ( n = 69; 43%); ( G ) ESR1 D538G -mutated tumors ( n = 97; 61%); or ( H ) ESR1 Y537S/N -mutated tumors ( n = 92; 58%). a Includes the following PIK3CA -mut: E545K, H1047R, and E542K among others. b Data not available for all patients. c HER2-low expression defined as IHC score of 1+ or 2+ with no amplification by ISH.

Year:

2024

PFS in patients who received prior ET+CDK4/6i ≥12 months in the metastatic setting. Kaplan–Meier estimates of PFS in patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months in the metastatic setting ( n = 159).

Year:

2024

PFS according to clinical subgroups. Kaplan–Meier estimates of PFS in patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months who, at screening, had the presence of ( A ) bone metastases ( n = 136; 86%); ( B ) liver and/or lung metastases ( n = 113; 71%); ( C ) n = 82; 52%); or ( D ) ≥3 metastatic sites ( n = 53; 33%). a Eighty-five percent of patients had bone and other sites of metastases (30% of these patients had no liver or lung involvement). b Fifty-five percent of patients had liver and other sites of metastases (10% of these patients had no lung or bone involvement); 25% of patients had lung and other sites of metastases (2% of these patients had no liver or bone involvement). c The number of metastatic sites was available for 135 of 159 patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months.

Year:

2024

Purpose: Postpartum breast cancer patients diagnosed after cessation of breastfeeding (post-weaning, PP-BC PW ), have a particularly poor prognosis compared to patients diagnosed during lactation (PP-BC DL ), or to pregnant (Pr-BC) and nulliparous (NP-BC) patients, irrespective of standard prognostic characteristics. Animal studies point to a role of the involution process in stimulation of tumor growth in the mammary gland. However, in women, the molecular mechanisms that underlie this poor prognosis of PP-BC PW patients remain vastly underexplored, due to of lack of adequate patient numbers and outcome data. Experimental Design: We explored whether distinct prognostic features, common to all breast cancer molecular subtypes, exist in postpartum tumor tissue. Using detailed breastfeeding data, we delineated the post-weaning period in PP-BC as a surrogate for mammary gland involution and performed whole transcriptome sequencing, immunohistochemical and (multiplex) immunofluorescent analyses on tumor tissue of PP-BC PW , PP-BC DL , Pr-BC and NP-BC patients. Results: We found that PP-BC PW patients having a low expression level of an immunoglobulin gene signature, but high infiltration of plasma B-cells, have an increased risk for metastasis and death. Although PP-BC PW tumor tissue was also characterized by an increase in CD8+ cytotoxic T-cells and reduced distance among these cell types, these parameters were not associated with differential clinical outcomes among groups. Conclusion: These data point to the importance of plasma B-cells in the post-weaning mammary tumor microenvironment regarding the poor prognosis of PP-BC PW patients. Future prospective and in-depth research needs to further explore the role of B-cell immunobiology in this specific group of young breast cancer patients.

Year:

2024

Purpose: Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i). In patients with ESR1-mutated tumors, we evaluated the efficacy and safety of elacestrant versus SOC based on prior ET+CDK4/6i duration and in clinical subgroups with prior ET+CDK4/6i ≥12 months. Patients and Methods: EMERALD, an open-label phase III trial, randomly assigned patients with ER+, HER2− metastatic breast cancer who had received 1–2 prior lines of ET, mandatory CDK4/6i, and ≤1 chemotherapy to elacestrant (345 mg daily) or SOC (aromatase inhibitor or fulvestrant). PFS was assessed across subgroups in post hoc exploratory analyses without adjustment for multiple testing. Results: In patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months, the median PFS for elacestrant versus SOC was 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26–0.63). In this population, the median PFS (in months) for elacestrant versus SOC was 9.1 versus 1.9 (bone metastases), 7.3 versus 1.9 (liver and/or lung metastases), 9.0 versus 1.9 (<3 metastatic sites), 10.8 versus 1.8 (≥3 metastatic sites), 5.5 versus 1.9 (PIK3 catalytic subunit α mutation), 8.6 versus 1.9 (tumor protein p53 gene mutation), 9.0 versus 1.9 (HER2-low), 9.0 versus 1.9 (ESR1D538G-mutated tumors), and 9.0 versus 1.9 (ESR1Y537S/N-mutated tumors). Subgroup safety was consistent with the overall population. Conclusions: The duration of prior ET+CDK4/6i ≥12 months in metastatic breast cancer was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC and was consistent across all subgroups evaluated in patients with ER+, HER2−, ESR1-mutated tumors.

Year:

2024

PURPOSE AMEERA-5 investigated amcenestrant (oral selective estrogen receptor [ER] degrader) plus palbociclib versus letrozole plus palbociclib as first-line treatment for ER-positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced/metastatic breast cancer (aBC). MATERIALS AND METHODS In AMEERA-5 (ClinicalTrials.gov identifier: NCT04478266 ), a double-blind, double-dummy, international phase III trial, adult pre-/post-menopausal women and men without previous systemic therapy for ER+/HER2– aBC were randomly assigned 1:1 to amcenestrant 200 mg once daily + standard palbociclib dosage (125 mg once daily, 21 days on/7 days off) or letrozole 2.5 mg once daily + standard palbociclib dosage, stratified by de novo metastatic disease, postmenopausal women, and visceral metastasis. The primary end point was progression-free survival (PFS), compared using a stratified log-rank test with one-sided type I error rate of 2.5%. Secondary end points included overall survival (key secondary), pharmacokinetics, and safety. RESULTS Between October 14, 2020, and December 2, 2021, 1,068 patients were randomly assigned to amcenestrant + palbociclib (N = 534) or letrozole + palbociclib (N = 534). At the interim analysis (median follow-up 8.4 months), the stratified hazard ratio for PFS was 1.209 (95% CI, 0.939 to 1.557; one-sided P value = .9304); therefore, the study was stopped for futility. The 6-month PFS rate was 82.7% (95% CI, 79.0 to 85.8) with amcenestrant + palbociclib versus 86.9% (95% CI, 83.5 to 89.6) with letrozole + palbociclib. In the amcenestrant + palbociclib versus letrozole + palbociclib groups, treatment-emergent adverse events (any grade) occurred in 85.6% versus 85.4% of patients and grade ≥3 events in 46.3% versus 60.8%, respectively. CONCLUSION The AMEERA-5 study was discontinued on the basis of the recommendation of the data monitoring committee at the interim futility analysis. No new safety signals were identified.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (30)

Anne Vincent‐Salomon

Professor (associate)

Université Paris Dauphine-PSL

FRANCE
View details

Katarzyna Joanna Jerzak

University of Toronto

CANADA
View details

Joyce O'Shaughnessy

Baylor University Medical Center

UNITED STATES
View details

François Bertucci

Professor

Institut Paoli-Calmettes

FRANCE
View details

Lodewyk Wessels

Professor

Delft University of Technology

NETHERLANDS
View details

Christine Desmedt

Head of Laboratory for Translational Breast Cancer Research

KU Leuven

BELGIUM
View details

Kristel Van Calsteren

KU Leuven

BELGIUM
View details

Diether Lambrechts

Science Director

KU Leuven

BELGIUM
View details

Francois-Clement Bidard

Professor of Medical Oncology

Institut Curie

FRANCE
View details

Nadia Harbeck

-

GERMANY
View details

Hope Rugo

Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology

City Of Hope National Medical Center

UNITED STATES
View details

Kelly K Hunt

Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Peter Schmid

Professor of Cancer Medicine and Honorary Consultant in Medical Oncology, Centre Lead, Centre for Experimental Cancer Medicine

Barts Cancer Institute

UNITED KINGDOM
View details

Federica Grillo

Assistant Professor

University of Genoa

ITALY
View details

Matteo Lambertini

University of Genova

ITALY
View details

Peter Fasching

-

GERMANY
View details

Swati Kulkarni

Professor of Surgery

Northwestern University

UNITED STATES
View details

Frédéric Amant

Antoni van Leeuwenhoek Nederlands Kanker Instituut

NETHERLANDS
View details

Ellen Warner

University of Toronto

CANADA
View details

Sara Hurvitz

Professor, Division Head

Washington University School of Medicine

UNITED STATES
View details

Elia Mario Biganzoli

Full Professor Medical Statistics

University of Milan

ITALY
View details

Virginia Kaklamani

Professor

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Aditya Bardia

UCLA Health

UNITED STATES
View details

Charlotte Maggen

Vrije Universiteit Brussel

BELGIUM
View details

Miguel Martin

Universidad Complutense de Madrid

SPAIN
View details

Gabriele Zoppoli

University of Genoa

ITALY
View details

Manali Bhave

Assistant Professor

Winship Cancer Institute of Emory University

UNITED STATES
View details

Sophia Leduc

Vrije Universiteit Brussel

BELGIUM
View details

Eva M. Ciruelos-Gil

Universidad Complutense de Madrid

SPAIN
View details

Fedro Peccatori

Director, Fertility nd Procreation in Oncology Unit

European Institute of Oncology

ITALY
View details